Wednesday, 18 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:06 PM ET 8-K
Financial Results Backblaze, Inc. BLZE

Backblaze Financial Results

Backblaze reported Q3 2026 financial results with total revenue of $46.7 million, up 26% year-over-year, driven by 47% growth in its B2 Cloud Storage segment. The company significantly improved its bottom line, narrowing its net loss to $2.4 million and achieving an Adjusted EBITDA margin of 33%.

Term
Q3 2026

“Q3 2026 was another strong quarter, with B2 revenue growth accelerating to 47% year over year, up from 28% a year ago, reflecting broad-based momentum across our customer base.”

Gleb Budman, co-founder and CEO of Backblaze
4:06 PM ET 8-K
Capital Raise ISQ Open Infrastructure Co LLC

ISQ Open Infrastructure Co Capital Raise of $29.5M

ISQ Open Infrastructure Company LLC issued and sold unregistered shares across multiple classes for total aggregate net consideration of approximately $29.5 million. The shares were sold to investors for cash and issued to independent directors for services rendered. The company also reported its monthly Transactional Net Asset Value (NAV) per share as of September 30, 2026.

Value
$29.5M
4:06 PM ET 8-K
Financial Results Vertex Pharmaceuticals Inc VRTX

Vertex Pharmaceuticals Financial Results

Vertex Pharmaceuticals reported Q3 2026 revenue of $3.44 billion, a 12% increase year-over-year, driven by strong demand for its cystic fibrosis therapies and new product launches. The company raised its full-year 2026 revenue guidance to a range of $13.15 billion to $13.25 billion. During the quarter, Vertex also completed the $9 billion acquisition of Crinetics Pharmaceuticals and secured a $4.5 billion term loan.

“Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the Crinetics Pharmaceuticals acquisition.”

Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex

“With the potential povetacicept approval in IgAN coming later this month, we are well positioned to establish nephrology as our fifth commercial franchise and expand the reach of our transformative medicines to even more patients.”

Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex
4:06 PM ET 8-K
Investor Presentation Independent Bank Corp INDB

Independent Bank Investor Presentation

Independent Bank Corp. filed an investor presentation to be used at the KBW 2026 Boston Bank Day on November 3, 2026. The presentation highlights the company's $25.0 billion in total assets and record operating EPS of $1.90 for the third quarter of 2026.

4:06 PM ET 8-K
Financial Results Travere Therapeutics, Inc. TVTX

Travere Therapeutics Financial Results

Travere Therapeutics reported Q3 2026 financial results, highlighted by $200.2 million in FILSPARI net product sales, representing 120% year-over-year growth. The company is advancing its Phase 3 HARMONY study of pegtibatinase with topline results expected in the second half of 2027 and plans to submit an IND for civorebrutinib by year-end.

“Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to expand our reach in IgAN and FSGS.”

Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics

“As I prepare to transition leadership to Bradley Campbell in December, I have never been more confident in Travere’s future, supported by an exceptional team, an expanding pipeline and a shared commitment to delivering hope to patients.”

Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics
4:06 PM ET 8-K
Other 8-K Filing Outdoor Specialty Products, Inc. ODRS

Outdoor Specialty Products Other 8-K Filing

Outdoor Specialty Products, Inc. filed a Certificate of Designation with the Nevada Secretary of State to establish a new series of 100 shares of Series A Preferred Stock. This action was taken out of the company's existing 10,000,000 authorized shares of preferred stock. The filing defines the voting powers, preferences, and rights of this new series, though no shares were reported as issued or sold in this filing.

4:06 PM ET 8-K
Executive Compensation Jerash Holdings (US), Inc. JRSH

Jerash Holdings Executive Compensation

Jerash Holdings restructured the compensation for its CEO Choi Lin Hung and Chairman Ng Tsze Lun by terminating existing consulting agreements with their respective entities and entering into direct employment agreements. Both executives will receive a monthly base salary of HK$297,000 plus an end-of-year payment equal to one month's salary under the new arrangements effective November 1, 2026.

Counterparty
Choi Lin Hung
4:06 PM ET Form 4
Insider Buying Bambusa Therapeutics, Inc. BBTX

Bambusa Therapeutics Director Helmut Wolfgang Jeggle Buys $6M of Stock

Helmut Wolfgang Jeggle, Director, bought 375,000 shares of Bambusa Therapeutics, Inc. at $16.00 a share, worth $6M in total on Nov 2, 2026. Shares held after the trade: 9,264,301 (+4.2%).

Value
$6M
Shares
375,000
Price
$16.00
Role
Director
Holding change
+4.2%
Trade date
Nov 2, 2026
4:06 PM ET 8-K
Executive Compensation 10x Genomics, Inc. TXG

10x Genomics Executive Compensation

10x Genomics appointed Ansuman Satpathy and Joseph Gilliam to its Board of Directors as Class III directors. Both will receive compensation under the company's Non-Employee Director Compensation Policy, including an annual cash retainer of $60,000 and a one-time restricted stock unit grant valued at $400,000.

4:06 PM ET 8-K
Divestiture Theriva Biologics, Inc. TOVX

Theriva Biologics Divestiture to Biossil Labs Inc.

Theriva Biologics completed the sale of its antibiotic-degrading enzyme portfolio, including SYN-004 (ribaxamase), to Biossil Labs Inc. for an upfront payment of $350,000. Theriva is eligible for up to $91 million in regulatory and sales milestones plus royalties, while Biossil assumes all future development costs and responsibilities.

Counterparty
Biossil Labs Inc.
4:06 PM ET 8-K
Loan & Debt Southwest Airlines Co LUV

Southwest Airlines $1.25B Debt Financing with U.S. Bank Trust Company, National Association

Southwest Airlines Co. completed a public offering of $1.25 billion in senior notes, consisting of $600 million of 5.750% notes due 2029 and $650 million of 6.000% notes due 2031. The notes were issued under an existing shelf registration statement to provide the company with long-term debt financing.

Value
$1.25B
Counterparty
U.S. Bank Trust Company, National Association
Term
through 2031
4:06 PM ET 8-K
Loan & Debt Avis Budget Group, Inc. CAR

Avis Budget Group $350M Debt Financing

Avis Budget Group's subsidiaries have issued a notice to redeem all $350 million of their outstanding 5.750% Senior Notes due July 2027. The redemption is scheduled for December 30, 2026, at a price of 100% of the principal amount plus accrued interest.

Value
$350M
4:06 PM ET 8-K
Leadership Change AbbVie Inc. ABBV

AbbVie Leadership Change

Jennifer L. Davis, a Class II director, notified AbbVie of her intent to resign from the Board of Directors effective November 2, 2026. Her departure follows her appointment as CEO of Align Technology, Inc. and is not due to any disagreement with the company.

4:06 PM ET 8-K
Executive Compensation Elme Communities ELMES

Elme Communities Executive Compensation

Elme Communities approved the termination of retention agreements for CEO Paul McDermott, COO Tiffany Butcher, and CFO W. Drew Hammond as the company winds up its affairs. The officers will receive cash lump sum payments totaling approximately $7.75 million ($5.06M, $1.66M, and $1.03M respectively) effective November 6, 2026. Following the company's dissolution, Hammond and Butcher are expected to enter into consulting agreements with the Liquidating Trust.

4:06 PM ET Form 4
Insider Selling Corbus Pharmaceuticals Holdings, Inc. CRBP

Corbus Pharmaceuticals Holdings Insider Cormorant Asset Management LP Sells $1.74M of Stock

Cormorant Asset Management LP sold 425,000 shares of Corbus Pharmaceuticals Holdings, Inc. at $4.10 a share, worth $1.74M in total on Oct 29, 2026. Shares held after the trade: 1,919,971 (-18.1%).

Value
$1.74M
Shares
425,000
Price
$4.10
Holding change
-18.1%
Trade date
Oct 29, 2026
4:06 PM ET 10-Q
Financial Results Shore Bancshares Inc SHBI

Shore Bancshares Q3 2026 Results: Net Income $16.8M, Up 16.9% YoY

Shore Bancshares, Inc. reported net income of $16.8 million for the third quarter of 2026, up from $14.3 million in the same period of 2025. The company saw a significant increase in net interest income to $55.1 million, driven by higher interest on loans, while total assets grew to $6.45 billion as of September 30, 2026.

Key figure
Net income $16.8M · +16.9% YoY
4:05 PM ET 10-Q
Financial Results Syndax Pharmaceuticals Inc SNDX

Syndax Pharmaceuticals Q3 2026 Results: Net Loss of $49.4M, Loss Narrows

Syndax Pharmaceuticals reported a significant increase in total revenues to $221.0 million for the nine months ended September 30, 2026, compared to $103.6 million in the prior year, driven by product sales of REVUFORJ and NIKTIMVO. Despite higher revenues, the company recorded a net loss of $141.5 million for the period, though this was an improvement from the $217.4 million loss in 2025. The balance sheet was strengthened by the issuance of a $250 million convertible note.

Key figure
Net loss $49.4M
4:05 PM ET Form 4
Insider Selling Business First Bancshares, Inc. BFST

Business First Bancshares Insider George W. Cummings III Sells $583K of Stock

George W. Cummings III sold 18,373 shares of Business First Bancshares, Inc. at $31.73 a share, worth $583K in total on Oct 29, 2026. Shares held after the trade: 165,372 (-10.0%).

Value
$583K
Shares
18,373
Price
$31.73
Holding change
-10.0%
Trade date
Oct 29, 2026
4:05 PM ET 8-K
Financial Results Tactile Systems Technology Inc TCMD

Tactile Systems Technology Financial Results

Tactile Systems Technology reported Q3 2026 total revenue of $91.9 million, a 7% increase year-over-year driven by 13% growth in its core lymphedema product line. While gross margin expanded to 77%, net income decreased to $7.2 million from $8.2 million in the prior year due to increased operating expenses supporting growth initiatives.

Term
Q3 2026

“Our results underscore the strength and durability of our core lymphedema business, which delivered its fifth consecutive quarter of double-digit year-over-year revenue growth, while gross margin expanded for the 12th consecutive quarter.”

Sheri Dodd, Chief Executive Officer of Tactile Medical

“We are positioned to capture that opportunity through three connected strategic priorities: expanding access to care, creating value across the patient journey, and broadening treatment options.”

Sheri Dodd, Chief Executive Officer of Tactile Medical
4:05 PM ET 8-K
Financial Results Capital Southwest Corp CSWC

Capital Southwest Financial Results

Capital Southwest reported its second fiscal quarter 2027 results, highlighted by a record $391 million in originations and the formation of a new technology-focused joint venture, Desert Star, with Trinity Capital. The company generated pre-tax net investment income of $0.58 per share and maintained a total investment portfolio of $2.4 billion.

Term
Q2 2027

“Capital Southwest delivered the largest origination quarter in our history, with approximately $391 million of originations across 14 new and 16 existing portfolio companies. We also committed $25 million to Desert Star, a new joint venture with Trinity Capital. This new joint venture gives us access to the technology lending market in partnership with Trinity, allowing us to gain exposure through a granular portfolio of investments in an area where we have not historically focused.”

Michael Sarner, President and Chief Executive Officer

“Our portfolio continued to generate strong earnings for our shareholders, producing $0.58 of pre-tax net investment income per share. Reflecting the strength of our earnings profile, the Board of Directors again declared a regular quarterly dividend of $0.58 per share, of which $0.1934 per share will be paid for each of October, November and December 2026, and a supplemental quarterly dividend of $0.06 to be paid in December 2026.”

Michael Sarner, President and Chief Executive Officer
4:05 PM ET 8-K
Loan & Debt WhiteHawk Minerals Corp. WHK

WhiteHawk Minerals Debt Financing Update with Capital One, National Association

WhiteHawk Minerals Corp.'s subsidiary entered into a third amendment to its existing credit agreement with Capital One and other lenders. The amendment modifies the agreement to permit the issuance of Series E and Series F Preferred Stock and removes references to Series D Preferred Stock.

Counterparty
Capital One, National Association
4:04 PM ET Form 4
Insider Selling Fifth Third Bancorp FITB

Fifth Third Bancorp EVP & Chief HR Officer Megan D. Burkhart Sells $21.2K of Stock

Megan D. Burkhart, EVP & Chief HR Officer, sold 398 shares of Fifth Third Bancorp at $53.45 a share, worth $21.2K in total on Oct 29, 2026. Shares held after the trade: 175,349 (-0.2%).

Value
$21.2K
Shares
397
Price
$53.45
Role
EVP & Chief HR Officer
Holding change
-0.2%
Trade date
Oct 29, 2026
4:04 PM ET Form 4
Insider Selling Visa Inc. V

Visa Insider Lloyd Carney Sells $251K of Stock

Lloyd Carney sold 605 shares of Visa Inc. at $415.28 a share, worth $251K in total on Oct 30, 2026. Shares held after the trade: 2,074 (-22.6%).

Value
$251K
Shares
605
Price
$415.28
Holding change
-22.6%
Trade date
Oct 30, 2026
4:04 PM ET Form 4
Insider Selling Hershey Co HSY

Hershey Insider Hershey Trust Co Trustee in Trust for Milton Hershey School Sells $3.26M of Stock

Hershey Trust Co Trustee in Trust for Milton Hershey School sold 20,000 shares of Hershey Co at $160.45 to $165.67 a share (average $163.22) in 11 transactions, worth $3.26M in total between Oct 29, 2026 and Oct 30, 2026. Shares held after the trade: 466,119 (-1.2%).

Value
$3.26M
Shares
20,000
Average price
$163.22
Holding change
-1.2%
Trade date
Oct 29, 2026 to Oct 30, 2026
4:04 PM ET 8-K
Financial Results National Presto Industries Inc NPK

National Presto Industries Financial Results

National Presto Industries reported a significant increase in third quarter 2026 results, with net sales rising 25% to $144.3 million and net earnings jumping to $20.0 million. Performance was driven by a 31.3% sales surge in the Defense segment due to backlog shipments and a one-time $8.1 million operating profit in Housewares following a Supreme Court-mandated tariff refund.

Term
Q3 2026

“Defense segment sales for the quarter were up $29 million or 31.3% from those reported in the comparable 2025 quarter, reflecting increased shipments from backlog. Sales for the Housewares/Small Appliances segment dipped nominally by $469 thousand or 2.1%. Safety segment sales, although still nominal, increased by $296,000 or 88.9%, reflecting increased distribution of a broader line. The Defense segment’s operating earnings were up $7.1 million or 61.8% from third quarter 2025 earnings largely due to the additional volume referenced above, along with a more favorable mix and increased operating efficiencies. In contrast to the prior year’s loss, Housewares/Small Appliance segment’s operating earnings were $8.1 million. Most of those earnings were attributable to a refund of a portion of the tariffs the segment had paid that the Supreme Court declared unauthorized in its February decision. The Safety segment reported a loss as anticipated.”

Maryjo Cohen, President
4:04 PM ET 8-K
Loan & Debt Aquabounty Technologies Inc AQB

Aquabounty Technologies $1M Debt Financing with Commas International LLC

AquaBounty Technologies issued a promissory note to Commas International LLC for a bridge loan of up to $1.0 million, with $0.5 million advanced immediately. The unsecured note bears an initial interest rate of 9% per annum and is intended to fund working capital and short-term liquidity needs. The lender is an affiliate of Univest Securities, which holds a significant equity stake in the company.

Value
$1M
Counterparty
Commas International LLC
Term
25 years
4:04 PM ET 8-K
Financial Results Advanced Energy Industries Inc AEIS

Advanced Energy Industries Financial Results

Advanced Energy Industries reported record Q3 2026 revenue of $696 million, up 50% year-over-year, driven by record performance in Semiconductor and Data Center Computing segments. Non-GAAP EPS of $3.65 exceeded the high end of the company's guidance range, and the company provided a strong Q4 outlook with revenue expected at $735 million +/- $25 million.

Term
Q3 2026

“We delivered record financial results again in the third quarter, with revenue in each of our markets growing sequentially and year-over-year. Our strategic investments and solid execution are enabling us to meet strengthening customer demand and deliver higher gross margin. With our Thailand factory ramp on track and growing revenue contribution from new products expected in 2027, we are confident in our ability to gain share and outgrow our markets.”

Steve Kelley, president and CEO of Advanced Energy
4:03 PM ET 10-Q
Financial Results Waystar Holding Corp. WAY

Waystar Holding Q3 2026 Results: Net Income $31M, Up 1.2% YoY

Waystar Holding Corp. reported a net income of $115.2 million for the nine months ended September 30, 2026, a significant increase from $92.1 million in the prior year period. Revenue grew to $959.2 million, driven by operational expansion, while the company also initiated common stock repurchases totaling $33.5 million during the period.

Key figure
Net income $31M · +1.2% YoY
4:03 PM ET 8-K
Financial Results Syndax Pharmaceuticals Inc SNDX

Syndax Pharmaceuticals Financial Results

Syndax Pharmaceuticals reported Q3 2026 total revenue of $83.3 million, an 82% year-over-year increase driven by strong sales of Revuforj and Niktimvo. The company also announced a leadership transition with Aaron A. Ondrey appointed as CFO effective November 9, 2026, succeeding the retiring Keith A. Goldan.

“We delivered another quarter of strong commercial results, generating $83 million in total revenue to Syndax. Revuforj net revenue grew to $61 million, driven by a 20% increase in new patients and an increasing number of patients on therapy in the post-transplant setting.”

Michael A. Metzger, Chief Executive Officer

“We look forward to sharing new Revuforj combination data in the fourth quarter that reinforce our confidence that our ongoing pivotal frontline trials could transform the treatment paradigm for newly diagnosed AML. We remain well positioned to be the first to deliver a menin inhibitor in the frontline, unlocking a multi-billion-dollar opportunity.”

Michael A. Metzger, Chief Executive Officer
4:03 PM ET 8-K
Executive Compensation Daily Journal Corp DJCO

Daily Journal Executive Compensation

Daily Journal Corporation entered into a new compensation agreement with Chairman and CEO Steven Myhill-Jones, setting an annual base salary of $700,000 and a target discretionary bonus of 50%. The agreement includes annual cash and equity incentives tied to 4% and 1% of the company's operating income respectively, along with a one-time cash award of $475,000 and a grant of 800 restricted stock units.

Counterparty
Steven Myhill-Jones
Term
through fiscal 2027

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.